Rury R. Holman

61.2k total citations · 21 hit papers
350 papers, 40.3k citations indexed

About

Rury R. Holman is a scholar working on Endocrinology, Diabetes and Metabolism, Cardiology and Cardiovascular Medicine and Surgery. According to data from OpenAlex, Rury R. Holman has authored 350 papers receiving a total of 40.3k indexed citations (citations by other indexed papers that have themselves been cited), including 265 papers in Endocrinology, Diabetes and Metabolism, 79 papers in Cardiology and Cardiovascular Medicine and 74 papers in Surgery. Recurrent topics in Rury R. Holman's work include Diabetes Treatment and Management (184 papers), Diabetes Management and Research (127 papers) and Diabetes, Cardiovascular Risks, and Lipoproteins (81 papers). Rury R. Holman is often cited by papers focused on Diabetes Treatment and Management (184 papers), Diabetes Management and Research (127 papers) and Diabetes, Cardiovascular Risks, and Lipoproteins (81 papers). Rury R. Holman collaborates with scholars based in United Kingdom, United States and Canada. Rury R. Holman's co-authors include David R. Matthews, H. A. W. Neil, Sanjoy K. Paul, M. Angelyn Bethel, Bernard Zinman, John B. Buse, Irene Stratton, Mayer B. Davidson, David M. Nathan and R. C. Turner and has published in prestigious journals such as New England Journal of Medicine, The Lancet and JAMA.

In The Last Decade

Rury R. Holman

339 papers receiving 38.4k citations

Hit Papers

10-Year Follow-up of Intensive Glucose Control in Typ... 1997 2026 2006 2016 2008 2008 2006 2015 2017 1000 2.0k 3.0k 4.0k 5.0k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. 10-Year Follow-up of Intensive Glucose Control in Type 2 Diabetes
    2008 5.5k citations Rury R. Holman, M. Angelyn Bethel et al. New England Journal of Medicine profile →
  2. Medical Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy
    2008 3.0k citations David M. Nathan, John B. Buse et al. Diabetes Care profile →
  3. Glycemic Durability of Rosiglitazone, Metformin, or Glyburide Monotherapy
    2006 2.2k citations Steven E. Kahn, Steven M. Haffner et al. New England Journal of Medicine profile →
  4. Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes
    2015 1.9k citations Jennifer B. Green, M. Angelyn Bethel et al. New England Journal of Medicine profile →
  5. Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes
    2017 1.5k citations Rury R. Holman, M. Angelyn Bethel et al. New England Journal of Medicine profile →
  6. Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom prospective diabetes study (UKPDS: 23)
    1998 1.5k citations R. C. Turner, Irene Stratton et al. profile →
  7. Development and progression of nephropathy in type 2 diabetes: The United Kingdom Prospective Diabetes Study (UKPDS 64)
    2003 1.3k citations Amanda Adler, Richard Stevens et al. profile →
  8. Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy
    2006 918 citations David M. Nathan, John B. Buse et al. Diabetes Care profile →
  9. Intensive glucose control and macrovascular outcomes in type 2 diabetes
    2009 829 citations Hertzel C. Gerstein, Rury R. Holman et al. Diabetologia profile →
  10. UKPDS 50: Risk factors for incidence and progression of retinopathy in Type II diabetes over 6 years from diagnosis
    2001 766 citations Irene Stratton, R. C. Turner et al. Diabetologia profile →
  11. Risk Factors for Renal Dysfunction in Type 2 Diabetes
    2006 731 citations C A Cull, Amanda Adler et al. profile →
  12. UKPDS 25: autoantibodies to islet-cell cytoplasm and glutamic acid decarboxylase for prediction of insulin requirement in type 2 diabetes
    1997 572 citations Irene Stratton, Susan E. Manley et al. profile →
  13. Medical management of hyperglycaemia in type 2 diabetes mellitus: a consensus algorithm for the initiation and adjustment of therapy
    2008 543 citations David M. Nathan, John B. Buse et al. Diabetologia profile →
  14. The UKPDS risk engine: a model for the risk of coronary heart disease in Type II diabetes (UKPDS 56)
    2001 543 citations Richard Stevens, Amanda Adler et al. profile →
  15. Addition of Biphasic, Prandial, or Basal Insulin to Oral Therapy in Type 2 Diabetes
    2007 529 citations Rury R. Holman, J Lévy et al. New England Journal of Medicine profile →
  16. Long-Term Follow-up after Tight Control of Blood Pressure in Type 2 Diabetes
    2008 504 citations Rury R. Holman, M. Angelyn Bethel et al. New England Journal of Medicine profile →
  17. Three-Year Efficacy of Complex Insulin Regimens in Type 2 Diabetes
    2009 502 citations Rury R. Holman, J Lévy et al. New England Journal of Medicine profile →
  18. Cardiovascular outcomes with glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes: a meta-analysis
    2017 413 citations M. Angelyn Bethel, Rishi Patel et al. profile →
  19. Effects of intensive glucose control on microvascular outcomes in patients with type 2 diabetes: a meta-analysis of individual participant data from randomised controlled trials
    2017 367 citations Hertzel C. Gerstein, Rury R. Holman et al. profile →
  20. Cardiovascular Outcomes Trials in Type 2 Diabetes: Where Do We Go From Here? Reflections From aDiabetes CareEditors’ Expert Forum
    2017 275 citations William T. Cefalu, Hertzel C. Gerstein et al. Diabetes Care profile →
  21. Post-trial monitoring of a randomised controlled trial of intensive glycaemic control in type 2 diabetes extended from 10 years to 24 years (UKPDS 91)
    2024 46 citations Amanda Adler, José Leal et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Rury R. Holman United Kingdom 76 29.6k 10.7k 9.2k 5.7k 3.9k 350 40.3k
John M. Lachin United States 80 22.7k 0.8× 8.6k 0.8× 10.6k 1.2× 5.2k 0.9× 3.2k 0.8× 283 37.0k
Lawrence A. Leiter Canada 95 23.6k 0.8× 9.5k 0.9× 14.4k 1.6× 7.7k 1.4× 5.3k 1.3× 544 40.0k
David M. Nathan United States 72 25.1k 0.8× 6.8k 0.6× 8.5k 0.9× 4.0k 0.7× 5.4k 1.4× 167 39.7k
William H. Herman United States 83 19.1k 0.6× 7.0k 0.6× 5.7k 0.6× 3.6k 0.6× 5.1k 1.3× 411 37.0k
Silvio E. Inzucchi United States 85 32.3k 1.1× 13.6k 1.3× 12.0k 1.3× 9.2k 1.6× 4.7k 1.2× 416 44.4k
Darren K. McGuire United States 85 25.8k 0.9× 9.8k 0.9× 10.7k 1.2× 14.1k 2.5× 3.7k 0.9× 461 40.0k
Vivian Fonseca United States 84 15.2k 0.5× 6.1k 0.6× 5.9k 0.6× 4.7k 0.8× 3.5k 0.9× 462 26.7k
Marja‐Riitta Taskinen Finland 100 24.4k 0.8× 8.8k 0.8× 16.8k 1.8× 11.6k 2.0× 6.6k 1.7× 571 46.0k
Bernard Zinman Canada 106 44.5k 1.5× 18.6k 1.7× 18.0k 2.0× 8.9k 1.6× 7.3k 1.9× 652 63.6k
Itamar Raz Israel 67 15.2k 0.5× 6.1k 0.6× 5.6k 0.6× 6.4k 1.1× 3.3k 0.8× 374 26.0k

Countries citing papers authored by Rury R. Holman

Since Specialization
Citations

This map shows the geographic impact of Rury R. Holman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Rury R. Holman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Rury R. Holman more than expected).

Fields of papers citing papers by Rury R. Holman

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Rury R. Holman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Rury R. Holman. The network helps show where Rury R. Holman may publish in the future.

Co-authorship network of co-authors of Rury R. Holman

This figure shows the co-authorship network connecting the top 25 collaborators of Rury R. Holman. A scholar is included among the top collaborators of Rury R. Holman based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Rury R. Holman. Rury R. Holman is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Dakin, Helen, et al.. (2024). Estimating Risk Factor Time Paths Among People with Type 2 Diabetes and QALY Gains from Risk Factor Management. PharmacoEconomics. 42(9). 1017–1028. 1 indexed citations
2.
Regan, Jessica A., Robert J. Mentz, Jennifer B. Green, et al.. (2023). Mitochondrial metabolites predict adverse cardiovascular events in individuals with diabetes. JCI Insight. 8(17). 9 indexed citations
3.
Bethel, M. Angelyn, Susanna R. Stevens, John B. Buse, et al.. (2020). Exploring the Possible Impact of Unbalanced Open-Label Drop-In of Glucose-Lowering Medications on EXSCEL Outcomes. Circulation. 141(17). 1360–1370. 10 indexed citations
4.
Leal, José, Shelby D. Reed, Rishi Patel, et al.. (2020). Benchmarking the Cost-Effectiveness of Interventions Delaying Diabetes: A Simulation Study Based on NAVIGATOR Data. Diabetes Care. 43(10). 2485–2492. 8 indexed citations
5.
Riddle, Matthew C., Lawrence Blonde, Hertzel C. Gerstein, et al.. (2019). Diabetes Care Editors’ Expert Forum 2018: Managing Big Data for Diabetes Research and Care. Diabetes Care. 42(6). 1136–1146. 8 indexed citations
6.
7.
Dennis, John, Beverley M. Shields, Anita Hill, et al.. (2018). Precision Medicine in Type 2 Diabetes: Clinical Markers of Insulin Resistance Are Associated With Altered Short- and Long-term Glycemic Response to DPP-4 Inhibitor Therapy. Diabetes Care. 41(4). 705–712. 59 indexed citations
8.
Holman, Rury R.. (2018). Clinically relevant results from cardiovascular outcome trials. Nature Reviews Endocrinology. 14(2). 67–68. 1 indexed citations
9.
Bethel, M. Angelyn, Samuel S. Engel, Susanna R. Stevens, et al.. (2018). Progression of glucose‐lowering diabetes therapy in TECOS. Endocrinology Diabetes & Metabolism. 2(1). e00053–e00053. 8 indexed citations
10.
Holman, Rury R., M. Angelyn Bethel, Robert J. Mentz, et al.. (2017). Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes. New England Journal of Medicine. 377(13). 1228–1239. 1503 indexed citations breakdown →
11.
Manley, Susan E., et al.. (2014). The effect of glibenclamide on insulin secretion at normal glucose concentrations. Diabetologia. 58(1). 43–49. 12 indexed citations
12.
Shen, Lan, Bimal R. Shah, Eric Reyes, et al.. (2012). Abstract 14642: Do Diuretics, Beta-Blockers, and Statins Increase the Risk of Diabetes in Patients with Impaired Glucose Tolerance? Insights from the NAVIGATOR Study. Circulation. 126. 1 indexed citations
13.
Holman, Rury R. & Julie Darbyshire. (2010). Insulin Regimens in Type 2 Diabetes REPLY. New England Journal of Medicine. 362. 960–960. 1 indexed citations
14.
Nathan, David M., John B. Buse, Mayer B. Davidson, et al.. (2007). Management of hyperglycaemia in type 2 diabetes mellitus: a consensus algorithm for the initiation and adjustment of therapy. Diabetologia. 51(1). 8–11. 81 indexed citations
15.
Holman, Rury R., et al.. (2003). Levels of beta-cell dysfunction and insulin resistance differ between Europeans and North Americans with recently-diagnosed diabetes in the ADOPT study. Diabetologia. 46. 1 indexed citations
16.
Gray, Alastair, Philip Clarke, Maria Raikou, et al.. (2001). An economic evaluation of atenolol vs. captopril in patients with Type 2 diabetes (UKPDS 54). Diabetic Medicine. 18(6). 438–444. 14 indexed citations
17.
Cull, C A, et al.. (1999). Plasma lipids and hypoglycaemic therapies over 6 years in Type 2 diabetic patients in the UKPDS. Diabetologia. 42. 1 indexed citations
18.
Dyson, Pamela, M S Hammersley, R J Morris, Rury R. Holman, & R. C. Turner. (1997). The fasting hyperglycaemia study: II. Randomized controlled trial of reinforced healthy-living advice in subjects with increased but not diabetic fasting plasma glucose. Metabolism. 46(12 Suppl 1). 50–55. 53 indexed citations
19.
Holman, Rury R., et al.. (1985). The Christmas feast.. BMJ. 291(6511). 1764–1765. 13 indexed citations
20.
Holman, Rury R., J Steemson, Pauline Darling, & R. C. Turner. (1984). LACK OF BENEFIT FROM GUAR ADMINISTRATION IN WELL CONTROLLED NON-INSULIN-DEPENDENT DIABETIC-PATIENTS. Diabetologia. 27. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by John M. Lachin Breakdown of academic impact, for papers by Lawrence A. Leiter Breakdown of academic impact, for papers by David M. Nathan Breakdown of academic impact, for papers by William H. Herman Breakdown of academic impact, for papers by Silvio E. Inzucchi Breakdown of academic impact, for papers by Darren K. McGuire Breakdown of academic impact, for papers by Vivian Fonseca Breakdown of academic impact, for papers by Marja‐Riitta Taskinen Breakdown of academic impact, for papers by Bernard Zinman Breakdown of academic impact, for papers by Itamar Raz
Rankless by CCL
2026